The proposed studies will seek to determine whether antitumor drugs exert direct actions on the phospholipase C second messenger system. Stimulation of phospholipase C leads to elevation of Ca++ and activation of protein kinase C, effects that are intimately involved with the regulation of proliferation, differentiation and immune responses. Signal transduction from agonist-stimulated receptors to phospholipase C is mediated by GTP-binding and hydrolyzing protein(s). Antimetabolites that deplete cellular GTP, i.e., selenazofurin and mycophenolic acid, or that form GTP analogs, i.e., 6-thioguanine, 3-deazaguanine and 8-azaguanine, may interfere with the activity of this class of stimulatory G protein(s). Agents that deplete CTP, such as pyrazofurin and 3-deazauridine, and 5-azacytidine, which forms 5- azaCTP, may interfere with synthesis of the CDP-diacylglycerol precursor of phosphatidylinositol. Our preliminary results show that selenazofurin reduces the agonist-stimulated inositol phosphate levels of proliferating and monocyte-induced HL-60 cells. The actions of these antimetabolites on the agonist- stimulated release of radiolabeled inositol phosphates, diacylglycerol and glucosamine will be determined by Dowex column chromatography, HPLC and TLC methods. Transport and metabolic uptake of (3H)inositol will be measured in proliferating and differentiated cells in the presence of CTP modulators. The response of the phospholipase C system to various putative growth factors, hormones and lymphokines will be characterized initally in the HL-60 cell line, using proliferating cells as well as cells that have been induced to mature toward graulocytic or moncytic phenotypes with dibutyryl cAMP, phorbol ester and 1 alpha, 25=dihydroxyvitamin D3. Later studies will compare the HOL-60 cell response with those of other types of inducible human leukemia cells. Drugs that alter basal or agonist-stimulated second messenger levels will be tested for effects on primary cellular responses such as ornithine decarboxylase activation in proliferating cells and superoxide anion production in differentiated cells. These studies may provide insights into the cytotoxic, differentiation-inducing and immunosuppressive effects of these antimetabolites and suggest ways to overcome host toxicities or enhance therapeutic efficacy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA047268-02
Application #
3190805
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
1988-06-01
Project End
1991-05-31
Budget Start
1989-06-01
Budget End
1990-05-31
Support Year
2
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Brown University
Department
Type
Schools of Medicine
DUNS #
001785542
City
Providence
State
RI
Country
United States
Zip Code
02912
Bussolari, J C; Ramesh, K; Stoeckler, J D et al. (1993) Synthesis and biological evaluation of N4-substituted imidazo- and v-triazolo[4,5-d]pyridazine nucleosides. J Med Chem 36:4113-20
Stoeckler, J D; Rosenfield, C G; Chu, S H et al. (1990) Inhibition of nucleoside transport by nitrobenzylthioformycin analogs. Biochem Pharmacol 40:615-9